Verbeek, Marcel M.

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis

Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,610

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis

Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology

Multiple Sclerosis Research StudiesCerebrospinal fluid and hydrocephalus

Cited by 764

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 614

A practical guide to immunoassay method validation

Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., et al. (2015) · Frontiers in Neurology

Clinical Laboratory Practices and Quality ControlAdvanced Biosensing Techniques and Applications

Cited by 546

Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men: A Randomized Clinical Trial

Ooms, S., Overeem, S., Besse, K., Rikkert, M. O., Verbeek, M., & Claassen, J. A. H. R. (2014) · JAMA Neurology

Sleep and Wakefulness ResearchAlzheimer's disease research and treatments

Cited by 438

Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update

del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine

Clinical Laboratory Practices and Quality ControlDementia and Cognitive Impairment Research

Cited by 343

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 290

Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy

Verbeek, M. M., Kremer, B. P. H., Rikkert, M. O., Van Domburg, P. H. M. F., Skehan, M. E., & Greenberg, S. M. (2009) · Annals of Neurology

Intracerebral and Subarachnoid Hemorrhage ResearchAlzheimer's disease research and treatments

Cited by 202

Impact of molecular imaging on the diagnostic process in a memory clinic

Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L. H., Wolfs, C. A. G., Aalten, P., et al. (2013) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchMedical Imaging Techniques and Applications

Cited by 194

Serum NFL discriminates Parkinson disease from atypical parkinsonisms

Marques, T. M., van Rumund, A., Oeckl, P., Kuiperij, H. B., Esselink, R. A. J., Bloem, B. R., Otto, M., & Verbeek, M. M. (2019) · Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 153

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

Gobom, J., Parnetti, L., Rosa-Neto, P., Vyhnalek, M., Gauthier, S., Cataldi, S., Lerch, O., Laczo, J., Cechova, K., Clarin, M., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM)

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 146

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy

Marques, T. M., Kuiperij, H. B., Bruinsma, I. B., van Rumund, A., Aerts, M. B., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M. (2017) · Molecular Neurobiology

Parkinson's Disease Mechanisms and TreatmentsMicroRNA in disease regulation

Cited by 141

Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients

Lamers, K. J. B., Vos, P., Verbeek, M. M., Rosmalen, F., van Geel, W. J. A., & van Engelen, B. G. M. (2003) · Brain Research Bulletin

S100 Proteins and AnnexinsTraumatic Brain Injury and Neurovascular Disturbances

Cited by 138

Lipoprotein Receptor-Related Protein-1 Mediates Amyloid-β-Mediated Cell Death of Cerebrovascular Cells

Wilhelmus, M. M. M., Otte-Höller, I., van Triel, J. J. J., Veerhuis, R., Maat-Schieman, M. L. C., Bu, G., de Waal, R. M. W., & Verbeek, M. M. (2007) · The American Journal of Pathology

Alzheimer's disease research and treatmentsBarrier Structure and Function Studies

Cited by 138

CSF neurofilament proteins in the differential diagnosis of dementia

de Jong, D., Jansen, R. W. M. M., Pijnenburg, Y. A. L., van Geel, W. J. A., Borm, G. F., Kremer, H. P. H., & Verbeek, M. M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 120

Neurofilament ELISA validation

Petzold, A., Altintas, A., Andreoni, L., Bartos, A., Berthele, A., Blankenstein, M. A., Buee, L., Castellazzi, M., Cepok, S., Comabella, M., et al. (2010) · Journal of Immunological Methods

Clinical Laboratory Practices and Quality ControlReliability and Agreement in Measurement

Cited by 105

Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia

de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 98

Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion

Oeckl, P., Anderl-Straub, S., Von Arnim, C. A. F., Baldeiras, I., Diehl-Schmid, J., Grimmer, T., Halbgebauer, S., Kort, A. M., Lima, M., Marques, T. M., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 94

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 88

Endotoxemia-induced inflammation and the effect on the human brain

van den Boogaard, M., Ramakers, B. P., van Alfen, N., van der Werf, S. P., Fick, W. F., Hoedemaekers, C. W., Verbeek, M. M., Schoonhoven, L., van der Hoeven, J. G., & Pickkers, P. (2010) · Critical Care

Intensive Care Unit Cognitive DisordersSepsis Diagnosis and Treatment

Cited by 84

Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease

Jongbloed, W., Bruggink, K. A., Kester, M. I., Visser, P.-J., Scheltens, P., Blankenstein, M. A., Verbeek, M. M., Teunissen, C. E., & Veerhuis, R. (2015) · Journal of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 68

Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study

Müller, M., Kuiperij, H. B., Versleijen, A. A. M., Chiasserini, D., Farotti, L., Baschieri, F., Parnetti, L., Struyfs, H., De Roeck, N., Luyckx, J., et al. (2016) · Journal of Alzheimer’s Disease

MicroRNA in disease regulationDementia and Cognitive Impairment Research

Cited by 41

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

Kruse, N., Persson, S., Alcolea, D., Bahl, J. M. C., Baldeiras, I., Capello, E., Chiasserini, D., Bocchio Chiavetto, L., Emersic, A., Engelborghs, S., et al. (2015) · Neurobiology of Aging

Parkinson's Disease Mechanisms and TreatmentsClinical Laboratory Practices and Quality Control

Cited by 38

CSF hypocretin-1 levels are normal in multiple-system atrophy

Abdo, W. F., Bloem, B. R., Kremer, H. P. H., Lammers, G. J., Verbeek, M. M., & Overeem, S. (2008) · Parkinsonism & Related Disorders

Sleep and Wakefulness ResearchParkinson's Disease Mechanisms and Treatments

Cited by 34